HC Wainwright Reiterates Buy Rating for Lexeo Therapeutics (NASDAQ:LXEO)

HC Wainwright reissued their buy rating on shares of Lexeo Therapeutics (NASDAQ:LXEO - Free Report) in a report released on Tuesday morning,Benzinga reports. The firm currently has a $23.00 target price on the stock.

A number of other research analysts have also weighed in on the company. Chardan Capital reissued a "buy" rating and issued a $25.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, March 25th. Leerink Partners cut their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a report on Monday, March 24th. Finally, Royal Bank of Canada decreased their price objective on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $22.20.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO traded down $0.19 during trading hours on Tuesday, hitting $1.98. 864,163 shares of the company were exchanged, compared to its average volume of 400,511. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics has a 52-week low of $1.45 and a 52-week high of $19.50. The stock has a market capitalization of $65.73 million, a price-to-earnings ratio of -0.63 and a beta of 1.52. The company's 50 day moving average price is $3.33 and its 200-day moving average price is $5.97.

Remove Ads

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.09. As a group, research analysts forecast that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Hedge Funds Weigh In On Lexeo Therapeutics

Several large investors have recently made changes to their positions in the company. Allostery Investments LP purchased a new position in Lexeo Therapeutics in the fourth quarter valued at $33,000. BNP Paribas Financial Markets increased its stake in shares of Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock valued at $50,000 after purchasing an additional 3,591 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Lexeo Therapeutics in the 4th quarter worth about $46,000. JPMorgan Chase & Co. raised its holdings in Lexeo Therapeutics by 135.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company's stock worth $93,000 after purchasing an additional 5,915 shares during the period. Finally, Price T Rowe Associates Inc. MD purchased a new position in Lexeo Therapeutics during the fourth quarter worth approximately $69,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.